STOCK TITAN
  1. Home
  2. News
  3. SPRC

SciSparc Ltd - SPRC STOCK NEWS

Welcome to our dedicated news page for SciSparc (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SciSparc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SciSparc's position in the market.

News
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
Rhea-AI Summary
SciSparc Ltd. (SPRC) announces successful results from a pre-clinical trial conducted in collaboration with Clearmind Medicine Inc. The trial focused on the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule, showing promising results for addressing obesity and related health challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
none
-
News
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
Rhea-AI Summary
SciSparc Ltd. (SPRC) announces that its joint venture, MitoCareX Bio, has achieved its second milestone by developing laboratory capabilities for cancer drug discovery. The joint venture focuses on targeting the nuclear encoded human mitochondrial carriers, with 53 members found to be altered in various malignancies. The achievement triggers an additional investment of $600,000 from SciSparc, resulting in the company holding 50.1% of MitoCareX Bio's share capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
Rhea-AI Summary
SciSparc Ltd. (SPRC) has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD) symptoms in children. The trial will enroll 60 participants between the ages of 5-18 years old to measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms. The trial is structured as a randomized, double-blind, placebo-controlled trial. SciSparc aims to reduce and alleviate the symptoms of autism with its pioneering treatment, partnering with the Soroka Medical Center and the National Autism Research Center to explore new territory in ASD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.22%
Tags
none
News
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
Rhea-AI Summary
SciSparc Ltd. (SPRC) is considering merging with a leading vehicle importer in Israel, transferring its pharmaceutical activities to a separate legal entity, and exploring the possibility of dividend distribution. The merger is expected to result in the Target Company becoming a wholly-owned subsidiary of SciSparc, and the combined company will continue to trade on the Nasdaq Capital Market under a new name. The Target Company's equity holders will hold approximately 80% of the Combined Company's share capital after the closing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.8%
Tags
acquisition
-
News
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
Rhea-AI Summary
SciSparc Ltd. (NASDAQ: SPRC) unveiled positive topline results from its Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center, indicating that its proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients. The trial showed a significant 23% reduction in agitation symptoms and a decline in eating and feeding difficulties, demonstrating the potential of SCI-110 in improving the lives of AD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.17%
Tags
none
-
News
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) initiates Phase IIb clinical trial for its proprietary drug candidate SCI-110 to treat Tourette Syndrome at Yale University, Tel Aviv Sourasky Medical Center, and Hannover Medical School. The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients using a daily oral treatment. Results from the Phase IIA trial at Yale University showed an average tic reduction of 21% and positive tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
clinical trial
News
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
Rhea-AI Summary
SciSparc Ltd. has received notice of acceptance for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. The patent has been granted by IP Australia. The global opioid market size was valued at $22.8 billion in 2022 and is expected to grow at a CAGR of 1.4% from 2023 to 2030. SciSparc's growing number of granted patents showcases the innovation in the company's pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.81%
Tags
none
-
News
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
Rhea-AI Summary
SciSparc receives acceptance for patent application in Australia for Combinations of Cannabinoids and N-Acylethanolamines. The patent strengthens the company's position in the cannabis sector and aligns with its core technologies to enhance the safety and therapeutic benefits of cannabinoids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
none
-
News
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
Rhea-AI Summary
SciSparc Ltd. announces closing of private placement, raising $5.026 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
Rhea-AI Summary
SciSparc announces private placement to raise $5.026 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags
none
Stock SPRC logo
SciSparc Ltd

Nasdaq:SPRC

SPRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SPRC Stock Data

4.11M
324.71k
0.02%
2.42%
6.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv